These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 20618796)

  • 1. Evidence-based health technology assessments for the Brazilian National Health System (Sistema Unico de Saúde, SUS) and for all.
    Atallah AN
    Sao Paulo Med J; 2009 May; 127(2):59-60. PubMed ID: 19597678
    [No Abstract]   [Full Text] [Related]  

  • 2. The NHS: assessing new technologies, NICE and value for money.
    Patel M
    Clin Med (Lond); 2011 Oct; 11(5):508; author reply 508-9. PubMed ID: 22034723
    [No Abstract]   [Full Text] [Related]  

  • 3. The policy debate over public investment in comparative effectiveness research.
    Rich EC
    J Gen Intern Med; 2009 Jun; 24(6):752-7. PubMed ID: 19381731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why is target trial emulation not being used in health technology assessment real-world data submissions?
    Castanon A; Duffield S; Ramagopalan S; Reynolds R
    J Comp Eff Res; 2024 Aug; 13(8):e240091. PubMed ID: 38850128
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-World Evidence-Current Developments and Perspectives.
    Schad F; Thronicke A
    Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
    Hao Y; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Values and evidence colliding: health technology assessment in child health.
    Ungar WJ; Prosser LA; Burnett HF
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):417-9. PubMed ID: 23977967
    [No Abstract]   [Full Text] [Related]  

  • 8. Conditionally funded field evaluations and practical trial design within a health technology assessment framework.
    Bowen JM; Patterson LL; O'Reilly D; Hopkins RB; Blackhouse G; Burke N; Xie F; Tarride JE; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):324-31. PubMed ID: 19394573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. For cost-reducing technologies, knowing markets is to change them.
    Huefner RP; Waitzman N; Andrade JD; Kern SE
    IEEE Eng Med Biol Mag; 2003; 22(1):26-31. PubMed ID: 12683059
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction: evaluation in analytic theory and political practice.
    Brown LD; Gusmano MK
    J Health Polit Policy Law; 2013 Dec; 38(6):1071-9. PubMed ID: 23974474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditionally funded field evaluations: PATHs coverage with evidence development program for Ontario.
    Goeree R; Chandra K; Tarride JE; O'Reilly D; Xie F; Bowen J; Blackhouse G; Hopkins R
    Value Health; 2010 Jun; 13 Suppl 1():S8-11. PubMed ID: 20618796
    [No Abstract]   [Full Text] [Related]  

  • 12. ['Medical technology assessment'; more than just efficacy].
    Buskens E
    Ned Tijdschr Geneeskd; 2000 Mar; 144(13):622-6. PubMed ID: 10761552
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.